Valeo Financial Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Valeo Financial Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-100	Closed	-$7K	–	2143
2021 Q1	$7K	Sell	100 -195	-66%	-$15.8K	﹤0.01%	1486
2020 Q4	$25K	Buy	295 +195	+195%	+$16.5K	﹤0.01%	978
2020 Q3	$7K	Sell	100 -6	-6%	-$393	﹤0.01%	1188
2020 Q2	$8K	Buy	106 +6	+6%	+$319	﹤0.01%	1387
2020 Q1	$4K	Buy	+100	New	+$4.57K	﹤0.01%	1389

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Valeo Financial Advisors's BHVN Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2021, closing a stake of 100 shares — an estimated $7K sold.

Valeo Financial Advisors first reported a position in BHVN in Q1 2020 and held it in 5 quarters. The position peaked at $25K in Q4 2020. 223 funds tracked by Wall St. Rank hold BHVN as of Q2 2021.

Valeo Financial Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2021 after selling out during the quarter.
Valeo Financial Advisors sold 100 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2021, an estimated $7K.
Valeo Financial Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 5 quarters.
Valeo Financial Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $25K in Q4 2020.
223 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.